Revolution Medicines (NASDAQ:RVMD) Upgraded at Evercore

Evercore upgraded shares of Revolution Medicines (NASDAQ:RVMD) to a strong-buy rating in a research note published on Wednesday morning,Zacks.com reports.

Several other brokerages have also recently commented on RVMD. HC Wainwright raised their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. JPMorgan Chase & Co. raised their price objective on shares of Revolution Medicines from $71.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Finally, Needham & Company LLC increased their target price on Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $78.94.

Revolution Medicines Stock Performance

Shares of NASDAQ RVMD opened at $102.02 on Wednesday. The stock’s fifty day simple moving average is $99.18 and its 200 day simple moving average is $70.35. The stock has a market capitalization of $20.22 billion, a price-to-earnings ratio of -17.26 and a beta of 1.01. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. Revolution Medicines has a 52-week low of $29.17 and a 52-week high of $124.49.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter last year, the business posted ($1.12) earnings per share. As a group, sell-side analysts forecast that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 5,447 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $418,438.54. Following the completion of the sale, the insider owned 278,600 shares in the company, valued at $21,402,052. This represents a 1.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark A. Goldsmith sold 15,394 shares of Revolution Medicines stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total transaction of $1,182,567.08. Following the sale, the insider directly owned 232,469 shares of the company’s stock, valued at $17,858,268.58. This trade represents a 6.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 113,792 shares of company stock worth $10,734,640 in the last 90 days. 8.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RVMD. New York State Common Retirement Fund increased its stake in shares of Revolution Medicines by 39.3% during the 3rd quarter. New York State Common Retirement Fund now owns 119,807 shares of the company’s stock worth $5,595,000 after purchasing an additional 33,821 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in Revolution Medicines in the third quarter worth $921,000. NEOS Investment Management LLC increased its position in Revolution Medicines by 34.7% during the third quarter. NEOS Investment Management LLC now owns 126,921 shares of the company’s stock worth $5,927,000 after buying an additional 32,694 shares during the last quarter. Tema Etfs LLC increased its position in Revolution Medicines by 34.7% during the third quarter. Tema Etfs LLC now owns 126,921 shares of the company’s stock worth $5,927,000 after buying an additional 32,694 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC bought a new position in Revolution Medicines during the third quarter valued at about $587,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: UBS initiated coverage with a “buy” rating, providing outside validation that could support more buying interest from institutional investors. Article Title
• Positive Sentiment: Evercore upgraded RVMD to “strong-buy,” adding another bullish analyst voice that may help sustain demand for the stock. Article Title
• Positive Sentiment: Coverage asking whether Revolution has found a cancer-treatment breakthrough is driving speculative interest; positive clinical readouts or clearer efficacy signals could be a material upside catalyst. Article Title
• Neutral Sentiment: The published Q4 2025 earnings call transcript provides management commentary and detail investors will parse for clinical progress, timelines and cost drivers; it’s a primary source but not new news by itself. Article Title
• Negative Sentiment: Revolution reported a wider-than-expected Q4 loss and guided 2026 operating expenses to $1.6B–$1.7B as it advances late‑stage RAS programs—higher burn and an earnings miss are immediate negatives that can pressure the share price until clinical milestones are demonstrated. Article Title

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.